Inovio Pharmaceuticals, Inc.
INOInovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development (June 2020).
Drugs in Pipeline
6
Phase 3 Programs
1
Upcoming Catalysts
2
Next Catalyst
Apr 20, 2026
10wMarket Overview
Stock performance and market intelligence
2 upcoming, 0 past
AI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
VGX-3100
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)
INO-3107
Respiratory Papillomatosis
INO-4700
Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
VGX 3100
Cervical Intraepithelial Neoplasia
INO-5401
Glioblastoma
INO-3112
Head and Neck Squamous Cell Cancer
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
VGX-3100 | Phase 3 | Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) | - |
INO-3107 | Phase 2 | Respiratory Papillomatosis | - |
INO-4700 | Phase 2 | Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | - |
VGX 3100 | Phase 2 | Cervical Intraepithelial Neoplasia | - |
INO-5401 | Phase 2 | Glioblastoma | - |
INO-3112 | Phase 2 | Head and Neck Squamous Cell Cancer | - |
Regulatory & News
Approvals, filings, and latest developments